Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - Adherex Technologies Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.21 per share a year ago, representing an earnings surprise of +75.00% [1] - The company posted revenues of $12.46 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 11.62%, and showing significant growth from year-ago revenues of $6.97 million [2] - Over the last four quarters, Adherex Technologies has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Adherex Technologies shares have increased approximately 23.1% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.02 on revenues of $13.42 million, and for the current fiscal year, it is -$0.25 on revenues of $42.99 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Adherex Technologies belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]